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neurons involve activation of Rac1 by the non-catalytic heavy chain (HCC/ 
A) 
Luis Solabre Valois , Vanilla (Hua) Shi , Paul Bishop , Bangfu Zhu , Yasuko Nakamura , Kevin 
A. Wilkinson *, Jeremy M. Henley *,1 
School of Biochemistry, Centre for Synaptic Plasticity, Biomedical Sciences Building, University of Bristol, Bristol BS8 1TD, UK   







A B S T R A C T   
Botulinum neurotoxins (BoNTs) are extremely potent naturally occurring poisons that act by silencing neuro-
transmission. Intriguingly, in addition to preventing presynaptic vesicle fusion, BoNT serotype A (BoNT/A) can 
also promote axonal regeneration in preclinical models. Here we report that the non-toxic C-terminal region of 
the receptor-binding domain of heavy chain BoNT/A (HCC/A) activates the small GTPase Rac1 and ERK pathway 
to potentiate axonal outgrowth, dendritic protrusion formation and synaptic vesicle release in hippocampal 
neurons. These data are consistent with HCC/A exerting neurotrophic properties, at least in part, independent of 
any BoNT catalytic activity or toxic effect.   
Introduction 
Botulinum neurotoxins (BoNTs) comprise a ~50 kDa light chain (LC) 
and a ~100 kDa heavy chain (HC) connected by a disulphide bridge 
(Montecucco and Schiavo, 1994). The LC is the catalytic domain and the 
HC is responsible for BoNT delivery into neurons. BoNTs are best 
characterised for their blockade of synaptic transmission at the neuro-
muscular junction (NMJ) (Montecucco and Schiavo, 1994; Sobel, 2005). 
Different BoNT subtypes are referred as serotoxins due to their different 
reactivity to antisera (Montecucco and Rasotto, 2015). The BoNT/A 
serotype, which is the subject of this study, was the most toxic substance 
known to humankind until BoNT/H serotype was identified that has a 
lethal dose lower than 1 ng/kg (Barash and Arnon, 2014). 
Intoxication by BoNT/A occurs in four stages: i) The C-terminal 
domain of the HC, HCC, binds to the cell membrane and is endocytosed 
into vesicles; ii) The N-terminal domain of the HC, HCN, assembles a 
channel in the vesicle membrane; iii) LC passes through the HCN channel 
into the cell and cleaves from the HC, iv) the catalytic LC binds 
synaptosomal-associated protein of 25 kDa (SNAP-25), a critical protein 
required for formation of the Soluble N-ethylmaleimide-sensitive factor 
Attachment Protein Receptor (SNARE) complex (Schiavo et al., 1994) 
and completely prevents neurotransmitter release (Dong et al., 2018), 
but does not block endocytosis (Neale et al., 1999). 
Interestingly, although BoNT/A predominantly enters neurons via 
synaptic vesicles at presynaptic terminals (Colasante et al., 2013) it can 
also gain access via binding to the fibroblast growth factor receptor 3 
(Fgfr3) which undergoes dynamin-independent endocytosis (Jacky 
et al., 2013; Solabre Valois et al., 2020). 
The extreme toxicity (LD50 in humans 0.1–1 ng/kg (Schiavo et al., 
1994)), neuronal specificity and long persistence of BoNT/A provide 
opportunities for therapeutic application. Examples include treatment of 
muscle spasm and hypertrophy, dysphagia (swallowing difficulties), 
hypersialorrhea (excessive salivation), hyperhidrosis (excessive sweat-
ing), puberophonia (high-pitched speech), vocal cord paralysis, tics, 
motor symptoms of cerebral palsy, cancer, neuropathic pain, migraine 
and major depression (for reviews see (Dutta et al., 2016; Pickett and 
Perrow, 2011). 
Because BoNTs are among the deadliest substances known, working 
with the full-length toxin is challenging and heavily restricted. There-
fore, to eliminate toxicity while retaining the ability to investigate other 
BoNT actions two main options are available. One is to study the HC in 
isolation by removing the catalytic LC. The HC is responsible for binding 
to surface proteins on neurons and forming the channel that allows the 
LC to enter the cytosol (Koriazova and Montal, 2003). The C-terminal 
* Corresponding authors. 
E-mail addresses: kevin.wilkinson@bristol.ac.uk (K.A. Wilkinson), j.m.henley@bristol.ac.uk (J.M. Henley).   
1 Centre for Neuroscience and Regenerative Medicine, Faculty of Science, University of Technology Sydney, Ultimo, NSW, Australia 
Contents lists available at ScienceDirect 
IBRO Neuroscience Reports 
journal homepage: www.sciencedirect.com/journal/IBRO-Neuroscience-Reports 
https://doi.org/10.1016/j.ibneur.2021.04.002 
Received 31 December 2020; Accepted 22 April 2021   
IBRO Neuroscience Reports 10 (2021) 196–207
197
domain of the HC (HCC) has been most closely implicated in binding and 
internalisation (Montecucco and Schiavo, 1994) although the N-termi-
nal domain, HCN, has also been reported to play a role (Ayyar et al., 
2015; Montecucco, 1998). 
Another option is to make the LC catalytically inactive and unable to 
cleave SNAP-25. The LC of BoNT/A is a zinc-dependent protease 
(Schiavo et al., 1992) with the Zn2+ ion fitting into a pocket formed by 
residues His223, Glu224, His227 and Glu262 (Lacy et al., 1998) with 
Glu224 indirectly binding zinc through a water molecule (for entire 
sequence see (Solabre Valois et al., 2020)). Mutation of Glu224 to a 
structurally similar but oppositely charged residue (E224Q), or dis-
rupting the zinc-binding pocket with a H227Y mutation completely 
remove LC catalytic activity (Kukreja et al., 2007; Zhou et al., 1995). 
Importantly, the inactive mutants enter neurons similar to catalytically 
active toxins (Baskaran et al., 2013). 
In addition to their remarkable toxicity BoNTs can also have positive 
effects on neuronal outgrowth. Motor neurons treated with BoNT/A 
sprout new axonal branches, an adaptive effect initially thought to be 
caused by the blockade of synaptic transmission (Brown et al., 1977; 
Holland and Brown, 1980). These new axonal branches innervate the 
same muscle fibres as the BoNT-intoxicated terminals, and have the 
same properties of calcium influx, impulse propagation and clustering of 
receptors at NMJ terminals as non-intoxicated control neurons 
(Angaut-Petit et al., 1990). BoNT/A also induces neurite sprouting in in 
vitro co-cultures of chick neuronal and muscle cells (Bonner et al., 
1994). Moreover, BoNT/A preconditioning enhances motor axon 
regeneration after mechanical injury in mice and in a human stem cell 
model (Franz et al., 2018). 
BoNT/A-induced neurite outgrowth has been proposed to be medi-
ated by cleavage of the SNARE protein SNAP-25 (de Paiva et al., 1999). 
However, a subsequent study using mouse embryonic spinal cord cul-
tures suggested that the C-terminal receptor binding domain of the 
heavy chain (HCC/A) of BoNT/A alone, which lacks any catalytic ac-
tivity on SNARE proteins, is responsible for neurite outgrowth (Coffield 
and Yan, 2009). How these HCC/A-mediated neurogenic effects occur 
remains unclear, but an attractive hypothesis is that it involves GTPases, 
which are a major target for pathogens (reviewed in (Spano and Galan, 
2018; Stein et al., 2012)) and are strongly implicated in neurite 
outgrowth (Luo et al. 1996). In particular, the small GTPase Rac1 is a 
substrate for ADP-ribosylation by the C3 component of botulinum toxin 
(Didsbury et al., 1989), and BoNT/A has been reported to upregulate 
expression of Rac1 and other small GTPases (Park et al., 2016). 
Rac1 acts as a ‘switch’ that binds GDP or GTP depending on its 
activation state (Um et al., 2014). GTP-bound Rac1 interacts with ef-
fectors to modulate actin dynamics and membrane remodelling (Mackay 
et al., 1995; Nobes and Hall, 1995; Ridley et al., 1992). Furthermore, 
Rac1 plays a central role in the regeneration of injured axons. More 
specifically, Rac1 inhibition with the specific inhibitor NSC23766 (Gao 
et al., 2004) reduces axonal density and impairs functional recovery in 
animal models of stroke, whereas Rac1 overexpression promotes axonal 
regeneration and functional recovery (Liu et al., 2018). 
Here we investigated the effectiveness of the catalytically inactive 
full-length mutant of BoNT/A, BoNT/A(0), which contains two point 
mutations, E224Q/H227Y (Solabre Valois et al., 2020) and HCC/A on 
neurite outgrowth. We performed experiments in neuronal stem cells 
and cultured rat hippocampal neurons in the presence or absence of the 
specific Rac1 inhibitor NSC23766 (Gao et al., 2004) to investigate the 
effects and mechanisms of BoNT/A actions. Our results indicate that 
HCC/A-mediated activation of Rac1 can contribute to neuronal differ-
entiation, filopodia formation/stabilisation, axonal outgrowth and 
potentiate synaptic vesicle release. 
Materials and methods 
Safety 
In the course of this project, no endo-positive (i.e. protease active 
therefore biologically hazardous) full-length botulinum neurotoxin was 
produced. It is important to note that in the context of BoNT production, 
protein activation specifically refers to hydrolysis of the peptide bond 
connecting LC and the HC and not to reconstitution of peptidase activity. 
Toxins labelled as (0) denote toxins in which protease activity has been 
removed by prior site-directed mutagenesis on their respective genes. 
This is only applicable to LC and BoNT, as HC does not present any 
protease action. All procedures were approved by the University of 
Bristol and Ipsen. 
Preparation of BoNT/A(0) and HCC/A 
The purified BoNT proteins for use in this study were prepared and 
provided by Ipsen (Oxford, UK) using proprietary protocols. 
Primary neuronal cultures 
All animal work was performed at University of Bristol and rats were 
sacrificed by schedule 1 lethal anaesthesia, following procedures in full 
compliance with ARRIVE guidelines and the U.K. Animals Scientific 
Procedures Act, 1986. Hippocampal neurons were prepared from E18 
Wistar rat embryos as previously described (Gurung et al., 2018). 
Briefly, cells were plated on poly-L-lysine-coated culture dishes at a 
density of 600,000 per well (6-well plates), or on to coverslips (200,000 
per coverslip) in Neurobasal medium (Gibco) containing 10% horse 
serum, 2% B27 (Gibco), and 2 mM glutamine, and incubated at 37 ◦C in 
humidified air supplemented with 5% CO2. Twenty-four hours later, the 
media was replaced by Neurobasal medium containing 2% B27 and 0.8 
mM glutamine, and incubated at 37 ◦C in humidified air supplemented 
with 5% CO2 until use. 
IncuCyte imaging 
To measure neurite outgrowth, we used a fully automated IncuCyte 
system for neurite length detection and calculating total neurite (i.e. 
axon and dendrite) outgrowth. Relative total neurite outgrowth values 
were calculated by referring each time point value of total neurite length 
to the total neurite length of the first image taken after cells were plated 
on DIV0 (i.e. the initial value is 1 for all the conditions and the value 
when a neurite doubles in length is 2). 
Neural stem cell cultures 
NSCs were obtained from E14 Wistar rat embryos and maintained 
undifferentiated in NSC growth medium as described previously (Zhu 
et al., 2018). Briefly, the forebrains were dissected out in a petri plate 
containing calcium and magnesium-free Hank’s balanced salt solution 
(HBSS; Gibco) with 2 mM Hepes. Samples were centrifuged at 200 g for 
1 min at room temperature (20–25 ◦C) and the supernatant was 
removed. 1 ml of pre-warmed StemPro Accutase (Gibco) was added to 
the tissue pellet and incubated at 37 ◦C for 10 min, and then dissociated 
by triturating 10 times in 10 ml of DMEM/F12 using a fire-polished 
pipette. The resultant cell suspension was filtered through a 70 µm 
cell strainer (BD Biosciences). The cells were then centrifuged at 200g 
for 5 min and the pellet was resuspended in 2 ml of stem cell prolifer-
ation medium comprising DMEM/F12 media supplemented with B27 
supplement (Gibco), 1 × Insulin-Transferrin-Sodium Selenite Supple-
ment (Gibco), 1 × Non-Essential Amino Acids Solution (Gibco), 20 
ng/ml of both EGF and bFGF (Preprotech), and 1 × Pen-Strep (Sigma 
Aldrich). Cells were counted and seeded in 6-well plates or T-25 culture 
flasks at a density of 1 × 105 ml− 1. The medium was changed every 48 h. 
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Neurospheres were passaged every 3–4 days when they were ~100 µm 
in diameter. 
For experiments involving neuronal differentiation, neurospheres 
were dissociated into single cells with Accutase and then plated at a 
density of 50,000 cells per coverslip in 24-well plates coated with poly- 
D-lysine (Sigma-Aldrich). NSCs were incubated in neurogenic differen-
tiation medium (the proliferation medium without EGF and bFGF but 
supplemented with 200 μM Ascorbic acid (Sigma Aldrich). The medium 
was changed every 2–3 days and the NSCs can be differentiated for up to 
14 days. All neural cell transfections were performed using Lipofect-
amine 2000 (Invitrogen) according to the manufacturer’s instructions. 
Only NSCs grow/proliferate as neurospheres in suspension and 80–90% 
purity was confirmed with the neural stem cell marker Nestin (Zhu et al., 
2018). 
Rac1 activity assay 
Rac1 activation was assessed using Active Rac1 Detection Kit by Cell 
Signaling Technologies (CST; Cat. No. 8815), according to the manu-
facturer’s instructions. An aliquot of total lysate was kept as a total Rac1 
control and the rest of the sample was applied to the column. Rac1 binds 
to an interacting protein retained on the column whereas inactive Rac1 
and other proteins flow through. The total Rac1 was eluted and assessed 
by quantitative Western blotting together with the total Rac1 control. 
SDS-PAGE and western blotting 
Samples for Western blotting were resolved by SDS-PAGE. Separated 
proteins were transferred to Immobilon-PVDF membrane (Merck Milli-
pore). After protein transfer, the membrane was briefly washed with 
TBS-T (1x Tris Buffered Saline, 0.1% Tween), blocked in 5% non-fat milk 
powder for 1 h and incubated with primary antibody diluted in 5% non- 
fat milk powder for 1 h at RT. Following incubation, the membrane was 
briefly washed three times with TBS-T and incubated with HRP- 
conjugated secondary antibody (Sigma-Aldrich, 1:10,000) diluted in 
3% non-fat milk powder for 45 min at RT. Membranes were washed 
three times for 5 min in TBS-T and incubated for 1 min at RT with 
Enhanced Chemiluminescence (ECL) substrate. Antibodies were diluted 
1:1000 (Rac1 from CST, Cat. No. 8815 and phospho-ERK1/2 from 
Sigma, Cat. No. M7802) or 1:300 (ERK1/2 from Sigma, Cat. No. 
M3807). ECL substrates were from Thermo Fisher Scientific and mem-
branes were developed using X-ray films. 
Immunocytochemistry 
Cells were fixed with pre-warmed 4% PFA for 10 min at room tem-
perature. Cells were then blocked and permeabilised with PBS con-
taining 3% (w/v) BSA and 0.1% Triton X-100 for 20 min at room 
temperature. Antibodies were mixed with PBS containing 3% (w/v) BSA 
to their appropriate working concentrations (Tuj1 antibody (Sigma- 
Aldrich, Cat No. T2200) at 1:200, and AnkG antibody (Neuromab, Cat 
No. N106136) at 1:500. These were incubated at 4ºC overnight. Then, 
coverslips were washed and incubated with fluorescently labelled sec-
ondary antibodies (from Jackson ImmunoResearch) in PBS containing 
3% (w/v) BSA and incubated for 1 h at room temperature. Coverslips 
were washed and mounted onto microscope slides and filopodia were 
counted as neurite protrusions with three requisites: 1) without an end 
wider than the body of the protrusion, 2) with a length at least twice as 
long as the width, 3) with a length shorter than 10 µm. 
Vesicle release 
Neurons were transfected with pcDNA3-SypHy and pmCherry-C3, as 
a morphological marker, using Lipofectamine 2000. BoNT/A(0) and 
HCC/A were applied to the culture after transfection. Transfections and 
release experiments were performed as described previously (Craig 
et al., 2015; Girach et al., 2013; Shi et al., 2020; Tang et al., 2015). 
Neurons were stimulated with a MASTER 8 pulse stimulator connected 
to a field stimulation imaging chamber with a slotted bath. Coverslips 
were mounted on the chamber and sealed with grease. The chamber was 
fitted into a compatible holder, connected to a gravity flow perfusion 
system and placed on the microscope stage. Buffers were pre-warmed to 
37 ◦C before the experiment. Stimulation protocols were as described in 
the literature (Burrone et al., 2006; Craig et al., 2015). Baseline re-
cordings were measured by stimulating the chamber with 2 Hz for 30 s. 
Then a stimulation of 66 APs at 33 Hz was applied to release the 
readily-releasable pool (RRP). 10 s after this, a stimulation of 900 APs at 
20 Hz was applied to release the reserve pool (RP). 120 s after the start of 
the experiment, ammonium chloride solution was perfused onto neu-
rons to reveal total levels of SypHy expression in neurons. Recording was 
stopped 60 s after NH4Cl addition. 25 µM CNQX and 50 µM D-AP5 were 
perfused throughout the experiment. BoNT/A(0) and HCC/A were not 
present in the solutions perfused. For each cell, 15 ROIs were analysed 
with non-responsive ROIs being discounted. Data were first normalised 
to background levels (ΔF/F0) and then expressed as a percentage of 
fluorescence obtained after NH4Cl perfusion (Fmax) (Girach et al., 2013; 
Tang et al., 2015). 
Statistical analysis 
Statistical analysis was done using MatLab and plots and graphs 
created using Microsoft Office Excel, as well as data handling and cal-
culations. The following tests were carried out: Student’s t-test (ttest), 
one-way Analysis of Variance (ANOVA) (anova1) followed by multiple 
comparison tests (multcompare) with Tukey’s correction (Tukey- 
Krame). Data are presented as mean ± Standard Error of the Mean (SEM) 
unless indicated otherwise. In all cases, the N value refers to the number 
of independent experiments performed. 
Results 
HCC/A activates Rac1 and ERK1/2 in neurons 
It has recently been reported that Rac1 promotes axonal regenera-
tion by enhancing intrinsic growth (Liu et al., 2018). We therefore tested 
whether full-length catalytically inactive BoNT/A(0) or the HCC/A 
domain alone (schematic shown in Fig. 1A) are capable of activating 
Rac1. Although the IC50 for BoNT/A cleavage of SNAP-25 is in the pM 
range, BoNT/A(0) reaches a binding/internalisation plateau at ~25 nM 
(Vazquez-Cintron et al., 2014), a concentration widely used in the field 
(Harper et al., 2011; Harper et al., 2016; Restani et al., 2012; Wang 
et al., 2015). For consistency, in this study we used both BoNT/A(0) and 
HCC/A at the same 25 nM concentration. 
Primary neurons were treated for 30 min with 25 nM BoNT/A(0) or 
HCC/A and GTP-bound (active) Rac1 was isolated from the lysate and 
quantified to determine the proportion of active Rac1 (Fig. 1B, C). The 
ratio of Rac1 bound to GTP was significantly higher in both BoNT/A(0) 
and HCC/A treated cells compared to control untreated cells (Control =
1; BoNT/A(0) = 1.69 ± 0.18; HCC/A = 1.49 ± 0.07; *p < 0.05 in both 
cases). 
The extracellular signal-regulated kinase (ERK) pathway is one of the 
main signalling nodes for neurite outgrowth (Perron and Bixby, 1999; 
Tsuda et al., 2011) and neuronal regeneration (Agthong et al., 2006, 
2009). Rac1 activation initiates downstream ERK signalling so we next 
investigated the effects of BoNT/A(0) and HCC/A on ERK activation. 
Neurons were treated for 30 min with 25 nM BoNT/A(0) or HCC/A, 
lysed and active phosphorylated ERK (pERK) assessed by Western 
blotting. Membranes were then stripped and re-probed for total ERK 
(Fig. 1D, E). Consistent with the Rac1 data, the proportion of phos-
phorylated ERK was significantly increased in both BoNT/A(0) and 
HCC/A treated cells compared to control untreated cells. The values 
were Control = 1; BoNT/A(0) = 2.20 ± 0.31 (*p < 0.05); HCC/A 
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= 2.52 ± 0.27 (**p < 0.01). Together, these data demonstrate that both 
full-length BoNT/A(0) and just the HCC/A binding domain effectively 
activate Rac1 and ERK via a pathway that does not require 
BoNT/A-mediated catalysis. 
HCC/A is sufficient to selectively promote Rac1-mediated axonal 
outgrowth 
We next sought to determine the effect of HCC/A on neurite (nascent 
axon and dendrite) outgrowth, and the possible dependence of this on 
Rac1. To do this, we used the Rac1 specific inhibitor NSC23766, which 
prevents activation by GEFs (Gao et al., 2004). 
DIV0 primary neurons were plated and treated with 25 nM BoNT/A 
(0) or HCC/A in the absence or presence of 100 µM NSC23766 (Hou 
et al., 2014). Total neurite outgrowth was measured for 140 h using an 
IncuCyte live cell imaging system (Fig. 2). Neurite detection and length 
measurement were performed by the system and fully automated (see 
Fig. S1 for example validation of neurite detection). Surprisingly, in the 
absence of NSC23766, no significant differences were detected in neu-
rite outgrowth between control, BoNT/A(0) and HCC/A groups. As ex-
pected, however, blockade of Rac1 by NSC23766 significantly reduced 
neurite outgrowth in all conditions (**p < 0.01; Fig. 2). 
At first sight our data are in apparent contrast to a previous report 
that both full-length active BoNT/A holotoxin and HCC/A alone increase 
neurite outgrowth in cultured mouse embryonic spinal cord neurons 
(Coffield and Yan, 2009). The maximum HCC/A concentration used by 
Coffield and Yan was 10 nM, while our working concentration was 
25 nM. More importantly, however, they used DRG sensory neurons 
rather than the hippocampal pyramidal neurons investigated here. This 
is significant because DRG neurons have a pseudo-unipolar morphology, 
containing only a single bifurcating axonal process (Nascimento et al., 
2018). Thus, the fact that neither BoNT/A(0) nor HCC/A induced an 
increase in total neurite outgrowth in our experiments could be attrib-
utable to the differences in morphology of the neuronal types investi-
gated. Indeed, BoNT/A is known to induce axonal sprouting at motor 
nerve terminals (Pamphlett, 1989), and Coffield and Yan’s images 
(Coffield and Yan, 2009) show most outgrowth corresponded to thin 
neurites with a terminal conical structure, suggestive of axons. 
Therefore, because most of the neurites in hippocampal neurons 
develop into dendrites we wondered whether BoNT/A might have a 
selective effect on axonal outgrowth, which was obscured in our Incu-
Cyte imaging. To examine this directly, we selectively monitored axonal 
outgrowth in our very young hippocampal cultures. DIV1 hippocampal 
neurons were plated and treated with 25 nM BoNT/A(0) or HCC/A in the 
absence or presence of 100 µM NSC23766. At DIV2, cells were fixed and 
stained with the axonal initial segment marker Ankyrin-G (AnkG) to 
identify axons (Fig. 3). In developing neurons, AnkG can be stained as 
early as DIV1 and stains all of the nascent axon (Freal et al., 2016; 
Kuijpers et al., 2016). 
BoNT/A and HCC/A treated neurons exhibited significantly 
increased axonal length compared to untreated controls. The axonal 
length values were: control = 53.9 ± 12.8 µm; BoNT/A(0) 
Fig. 1. BoNT/A(0) and HCC/A activate Rac1 and ERK1–2. 
A) Schematic representing the domains of BONT(0), 
including the HCC/A used here. B) Representative Western 
blot of samples from DIV14–17 cortical neurons treated 
with vehicle, 25 nM BoNT/A(0) or 25 nM HCC/A for 
30 min. Activated Rac1 was isolated using Active Rac1 
Detection Kit (Cell Signalling Technologies). Isolated active 
Rac1 and cell lysate (for total Rac1) were then subjected to 
Western blotting and probed for Rac1. C) Quantification of 
the results in B, represented by mean values ± SEM. 
ANOVA followed by Tukey post hoc test. *p < 0.05. N = 3. 
D) Representative Western blot from DIV14–17 cortical 
neurons treated with vehicle, 25 nM BoNT/A(0) or 25 nM 
HCC/A for 30 min. Membranes were probed with anti- 
pERK and anti-ERK antibodies. E) Quantification of the 
results in D, represented by mean values ± SEM. ANOVA 
followed by Tukey post hoc test. *p < 0.05, * *p < 0.01. 
N = 4.   
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= 153.3 ± 25.0 µm (**p < 0.01 compared to control) and HCC/A 
= 139.3 ± 13.3 µm (*p < 0.05 compared to control). However, in the 
presence of NSC23766, these values were reduced to control levels: 
52.6 ± 7.4 µm; BoNT/A(0) = 57.7 ± 11.0 µm; HCC/A 
= 55.6 ± 8.34 µm. These data, together with those of Coffield and Yan’s 
images (Coffield and Yan, 2009), suggest that HCC/A selectively pro-
motes axonal outgrowth, and that this effect requires activation of Rac1. 
HCC/A promotes the formation of dendritic protrusions 
Although our data suggest that HCC/A does not significantly alter 
nascent dendrite outgrowth we wondered if it affects formation of 
dendritic protrusions, i.e. filopodia that can mature into dendritic spines 
(Ziv and Smith, 1996), and if this also requires Rac1 activity (Yoshihara 
et al., 2009). To explore this possibility, we treated DIV14–15 hippo-
campal neurons with 25 nM BoNT/A(0) or HCC/A for 3 days in the 
absence or presence of 100 µM NSC23766 (Fig. 4). Neurons were 
transfected with eGFP prior to the treatment to allow visualisation of 
neuronal morphology. For these experiments we counted protrusions 
from the main body of the dendrite, meaning that both filopodia and 
early dendritic spines, which begin to appear at this developmental stage 
in our cultures, are included (Ashby et al., 2004; Martin et al., 2007). In 
our control neurons there were 3.31 ± 0.86 protrusions/100 µm length 
of dendrite. In toxin-treated cells these values were significantly higher 
with 7.42 ± 0.55 protrusions/100 µm for BoNT/A(0)-treated cells and 
7.40 ± 0.72 protrusions/100 µm for HCC/A-treated cells (*p < 0.05 
compared to control in both cases). No well-defined protrusions at all 
were observed for NSC23766-treated cells under any condition. Thus, 
analogous to our results for axonal outgrowth, these data suggest that 
HCC/A promotes the formation of dendritic protrusions, and that this 
process too requires Rac1 activity. 
HCC/A potentiates release of the reserve pool of synaptic vesicles 
Given that our data indicate that BoNT/A(0) and HCC/A promote 
both axonal outgrowth and increase the number of dendritic pro-
trusions, we next investigated other possible neurotrophic effects of 
BoNT, such as enhancement of presynaptic neurotransmitter release 
(Fig. 5). 
Hippocampal neurons were treated with 25 nM BoNT/A(0) or HCC/ 
Fig. 2. BoNT/A(0) and HCC/A do not globally enhance neurite outgrowth. A) Representative images of DIV7 hippocampal neurons grown in the absence or presence 
of 25 nM BoNT/A(0) or HCC/A with our without the Rac1 inhibitor NSC23766 (scale bar = 100 µM). B) Quantification of relative neurite outgrowth over time, 
represented as mean ± SEM. ANOVA followed by Tukey post hoc test, * *p < 0.01 at the end of the experiment. N = 4. 
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A for 3 days and the presynaptic vesicle release at individual boutons 
induced by electrical stimulation measured using synaptophysin 
pHluorin (SypHy; (Craig et al., 2015; Girach et al., 2013; Shi et al., 2020; 
Tang et al., 2015). The SypHy assay uses a pH-sensitive fluorophore 
reporter tagged to the extracellular region of synaptophysin to detect 
synaptic neurotransmitter release. At rest, SypHy fluorescence is 
quenched due to the acidic conditions inside the lumen of the vesicle. 
However, upon stimulation, vesicular fusion to the plasma membrane 
exposes the reporter to the neutral extracellular solution, enhancing 
fluorescence (Burrone et al., 2006). 
BoNT/A and HCC/A both increased release from the reserve pool of 
synaptic vesicles with peak values of: control = 38.5 ± 3.7; BoNT/A(0) 
= 46.7 ± 3.3; HCC/A = 60.0 ± 3.6 (Fig. 5). However, the increase in 
synaptic vesicle release was only significantly different between control 
and HCC/A groups (**p < 0.01) with no statistical difference between 
control and BoNT/A(0), or BoNT/A(0) and HCC/A. While the reason for 
these differences is currently unclear, our data suggest that HCC/A alone 
is sufficient to enhance presynaptic release. 
BoNT/A(0) promotes neurogenesis in a manner dependent on Rac1 
Our results so far demonstrate that BoNT/A possesses a number of 
neurotropic properties, namely the promotion of axonal growth, of 
dendritic filopodia and enhancement of neurotransmitter release. We 
therefore wondered whether BoNT/A was also capable of promoting 
neuronal differentiation. To investigate this, we examined the effects of 
HCC/A on directing neurogenesis of neural stem cells (NSCs) (Song et al., 
2012; Yuan et al., 2011). Neuronal differentiation of NSCs was assessed 
by measuring expression of the neuron-specific marker Class III 
β-tubulin (Tuj1) (Jiang and Oblinger, 1992; Katsetos et al., 2007). Cells 
were plated after neurosphere dissociation and treated with 25 nM 
BoNT/A(0) or HCC/A in the absence or presence of NSC23766. On 
DIV10, cells were fixed and stained with an antibody targeting Tuj1 
(Fig. 6A). 
Data were first analysed by examining the proportion of Tuj1- 
positive cells in each condition. Tuj1-positive cells made up 
7.70 ± 6.34% under control conditions in the absence of NSC23766, 
Fig. 3. BoNT/A(0) and HCC/A induce axon 
outgrowth in a manner that requires Rac1 ac-
tivity. A) Representative images of DIV2 hip-
pocampal neurons grown with 25 nM BoNT/A 
(0) or HCC/A in the absence or presence of 
100 µM NSC2736. Axons with positive AnkG 
staining are shown as red and outlined by 
dotted lines. Blue signal corresponds to nuclei 
(DAPI). Scale bar = 10 µm. B) Quantification of 
axonal outgrowth, represented as mean ± SEM. 
ANOVA followed by Tukey post hoc test, 
*p < 0.05, * *p < 0.01. Analysis of at least 3 
cells per coverslip using coverslips from 3 in-
dependent cultures per condition. N = 3.   
L. Solabre Valois et al.                                                                                                                                                                                                                         
IBRO Neuroscience Reports 10 (2021) 196–207
202
indicating minimal spontaneous differentiation. Both BoNT/A(0) and 
HCC/A dramatically promoted differentiation, with values of 
55.2 ± 3.2% (**p < 0.01) and 42.7 ± 3.7% (*p < 0.05), respectively. 
However, for NSC23766-treated conditions, the percentage of differen-
tiated cells went up to 90.5 ± 9.5% for the control, 87.8 ± 6.2% for 
BoNT/A(0)-treated cells and 86.3 ± 3.2% for HCC/A-treated cells 
(Fig. 6A, B). These values are significantly higher than the respective 
conditions without NSC2733 treatment. Importantly, however, the pro- 
differentiation effect of BoNT/A(0) and HCC/A were not observed in the 
presence of NSC23766. Nonetheless, these surprising results could be 
interpreted to suggest that either inhibition by NSC23766, or activation 
of Rac1 by BoNT/A(0) and HCC/A, or both, induce NSC differentiation. 
We note, however, the interpretation of the effect of NSC23766 is 
confounded by the fact that NSC23766 exerted a strong anti- 
proliferative effect on NSCs (Fig. S2A). The cell count per 10,000 µm2 
(100 ×100 µm) was 11.6 ± 0.4 for the control (a total of 217 cells), 
16.8 ± 4 (220 cells) for the group treated with BoNT/A(0) and 
18.5 ± 3.8 (247 cells) for the group treated with HCC/A. In presence of 
NSC23766, the number of cells per field was significantly reduced to 
2.77 ± 0.86 (*p < 0.05 compared to the corresponding NSC23766- 
lacking group, 52 cells), 1.65 ± 0.14 (**p < 0.01, 31 cells) and 
1.28 ± 0.24 (**p < 0.01, 34 cells). Thus, we conclude that the 
NSC23766-induced reduction of the cell count was responsible for the 
abnormal increase in the percentage of differentiation, and, since most 
surviving cells were differentiated, this suggests NSC23766 specifically 
depletes undifferentiated NSCs. 
We also analysed the number of Tuj1-positive cells per 10,000 µm2 
unit area (Fig. S1B). Both BoNT/A(0) and HCC/A increased the number 
of Tuj1-positive cells per unit area, and this effect was lost in the pres-
ence of NSC32766. For the control, 0.85 ± 0.70 cells were Tuj1-positive. 
BoNT/A(0) significantly increased the number of Tuj1-positive cells per 
unit area, to 6.40 ± 0.24 (**p < 0.01 compared to the control). HCC/A 
caused a similar effect, with 7.63 ± 1.1 Tuj1-positive cells per field 
(**p < 0.01 to the control). For NSC23766-treated groups, these values 
were 2.34 ± 0.44, 1.39 ± 0.14 and 1.01 ± 0.19 for the control, BoNT/A 
(0)-treated and HCC/A-treated conditions, respectively. 
In combination, our data suggest that Rac1 activation by BoNT/A(0) 
and HCC/A induce NSC differentiation and that, in the absence of Rac1 
activity, the neurogenic effect of BoNT is lost. Furthermore, we conclude 
that Rac1 is fundamental for NSC growth in vitro and its inhibition re-
sults in arrest of the cell cycle, as noted for colon cancer cells (Huang 
et al., 2018), and/or cell death by apoptosis (Stankiewicz et al., 2015). 
Discussion 
Here we show that the HCC/A heavy chain binding domain affects a 
Fig. 4. BoNT/A(0) and HC/A increase the number of 
dendritic protrusions. A) Representative images of 
DIV14–17 hippocampal neurons transfected with a plasmid 
encoding eGFP and treated for 3 days with 25 nM BoNT/A 
(0) or HCC/A in the absence or presence of 100 µM 
NSC23766. B) Quantification of the number of protrusions 
per unit of neurite length, represented as mean values 
± SEM. ANOVA followed by Tukey post hoc test. 
*p < 0.05. Analysis of at least 3 cells per coverslip using 
coverslips from 3 independent cultures per condition. 
N = 3. Scale bar = 10 µm.   
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range of neuronal properties, including axonal and filopodial 
outgrowth, synaptic vesicle release and NSC differentiation, with no 
requirement for BoNT catalytic activity. Moreover, we demonstrate that 
these actions require activation of Rac1. 
Axonal outgrowth 
We did not detect any effect of BoNT/A or HCC/A on total neurite 
outgrowth. However, using AnkG as a marker for neurites destined to be 
axons (Freal et al., 2016; Kuijpers et al., 2016), we demonstrate that 
HCC/A selectively promotes axonal outgrowth in hippocampal neurons, 
and that this effect is lost upon inhibition of Rac1. These data are 
Fig. 5. HCC/A promotes release of the reserve 
pool of synaptic vesicles, A) Representative 
images of from DIV14–16 hippocampal neurons 
transfected with SypHy and mCherry. Cells 
were treated for 3 days with 25 nM BoNT/A(0) 
or HCC/A and, after baseline recordings, stim-
ulated to release the readily-releasable pool of 
synaptic vesicles (66 APs at 33 Hz) followed, 
10 s later, by a stimulation of 900 APs at 20 Hz 
to release the reserve pool. The maximal fluo-
rescence was revealed by NH4Cl, which 
temporally equilibrates all intracellular com-
partments to the extracellular pH 7.4. B) 
Quantification of the SypHy signal, represented 
as mean ± SEM. Red arrows indicate stimula-
tions described in A. C) Quantification of 
reserve pool release showing the average ΔF/ 
Fmax comprising values from 10 s after the sec-
ond stimulation until the peak begins to subside 
at 70 s. Analysis of at least 3 cells per coverslip 
using coverslips from 3 independent cultures 
per condition. * *p < 0.01. N = 3.   
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consistent with the finding that overexpression of human Rac1 in mouse 
Purkinje cells induces axonal, but not dendritic, outgrowth (Luo et al., 
1996). Our results also agree with a study in DRG neurons where 
BoNT/A concentrations in the range 0.01 – 10 nM were reported to 
stimulate neuritogenesis (Coffield and Yan, 2009). Moreover, those 
authors observed similar results with the isolated HCC/A, suggesting 
that neuritogenesis could be initiated solely by the binding actions of 
BoNT/A to neurons. 
We also show that BoNT/A(0) and HCC/A activate ERK1/2. In mac-
rophages BoNT/A stimulates ERK phosphorylation via upregulation of 
Toll-like receptor 2 (TLR2) (Kim et al., 2015), and TLR2 promotes 
phosphorylation of ERK in neurons (Paulino et al., 2011). Therefore, it 
remains unclear if ERK1/2 activation is directly downstream of Rac1 
activation. Nonetheless, taken together, our data indicate that the 
axonal growth promoting effects of BoNT/A(0) or HCC/A preferentially 
act on nascent axons in a Rac1-dependent manner. 
Dendritic protrusions 
BoNT(0)/A and HCC/A induce dendritic protrusion formation in our 
cultures, and this effect is abolished by the Rac1 inhibitor NSC23766. It 
has been reported previously that Rac1 can enhance dendritic filopodia 
formation (Alvarez Julia et al., 2016; Galic et al., 2014) and their 
maturation into functional spines (Fiuza et al., 2013; Tashiro and Yuste, 
2004). It should be noted, however, that long-term treatment with 
NSC23766 will inhibit all Rac1 activity and impair many cellular func-
tions. For example, NSC23766, can induce apoptosis (although 
demonstrated at 200 µM, rather than the 100 µM used here (Stankiewicz 
et al., 2015)) and dendritic protrusions are pruned through pathways 
shared with apoptosis (Meng et al., 2015a) so we cannot completely 
exclude the possibility that the inhibition of filopodia formation by 
NSC23766, could be due to initiation of apoptotic, or other, pathways 
rather than a direct Rac1-mediated effect on filopodia formation. 
Notwithstanding these potential caveats, our data demonstrate a posi-
tive effect of HCC/A on the formation of dendritic protrusions. 
Vesicle release 
Surprisingly, while HCC/A significantly increased synaptic vesicle 
release from the presynaptic terminal, BoNT/A(0) did not. Importantly, 
Fig. 6. BoNT/A(0), HCC/A and NSC23766 increase NSC 
neuronal differentiation. A) Representative images of 
DIV10 NSCs grown in non-differentiated conditions in the 
absence or presence of 25 nM BoNT/A(0) or HC/A, with or 
without 100 µM NSC23766, and stained with anti-Tuj1 
(green) as a marker for differentiation and DAPI (blue) to 
stain nuclei. Scale bar = 10 µM. B) Quantification of the 
proportion of Tuj1-positive cells represented as mean 
± SEM. ANOVA followed by Tukey post hoc test. 
*p < 0.05, * *p < 0.01. Analysis of multiple fields of view 
per coverslip using coverslips from 3 independent cultures 
per condition. N = 3.   
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unlike HCC/A, full-length BoNT/A(0) can deliver LC/A(0) to the pre-
synaptic terminal (Vazquez-Cintron et al., 2014) where, despite being 
catalytically inactive, LC/A(0) binds to SNAP-25 (Pellett et al., 2011), 
possibly interfering with SNARE complex function. While this 
non-catalytic inhibitory interaction could prevent the enhanced synaptic 
vesicle release observed with HCC/A, the reasons for the differential 
effects of HCC/A and BoNT/A(0) on release are unclear and require 
further investigation. We postulate that Rac1 could be involved in the 
HCC/A-mediated potentiation of transmitter release. Consistent with 
this idea, loss of Rac1 impairs synaptic plasticity and spatial learning 
(Haditsch et al., 2013) and it also facilitates Ca2+-dependent exocytosis 
(Li et al., 2003). However, we were unable to test this hypothesis 
because the Rac1 inhibitor NSC23766 compromises neuronal viability 
and function. Indeed, inactivation of Rac1 by knock-out or NSC23766 
treatment elicits apoptosis (Stankiewicz and Linseman, 2014; Hua et al., 
2015). 
Neurogenesis 
In addition to structural and functional changes in neurons, we 
addressed the question of the potential influence of BoNT on neuro-
genesis. Our experiments indicate that BoNT/A(0) and HCC/A promote 
NSC differentiation, and that this effect is blocked by Rac1 inhibition. 
These findings are consistent with the previously reported roles of Rac1 
in promoting neurogenesis evoked through nerve growth factor (NGF) 
(Suzukawa et al., 2000) and by learning (Haditsch et al., 2013). 
Conversely, inhibition of Rac1 or downstream Notch2 signalling 
pathways have been suggested to enhance NSC differentiation (Meng 
et al., 2015b). However, this is likely due to the arrest of cell prolifer-
ation rather than a direct neurogenic effect. Indeed, in our cells, Rac1 
inhibition arrested proliferation. Rac1 elicits neuroprotective effects 
(Stankiewicz et al., 2015) and an important factor in NSC proliferation is 
that low density leads to spontaneous differentiation (Cha et al., 2017). 
We propose that the enhanced differentiation we observed upon Rac1 
inhibition corresponds to an apoptotic effect followed by spontaneous 
differentiation caused by the low density of culture, but further work 
will be required to fully test this hypothesis. 
Conclusion 
In conclusion, we have demonstrated that BoNT/A elicits neuro-
trophic effects via HCC/A-mediated activation of Rac1. Properly 
administered, BoNT/A has already been shown to be a safe drug and, 
indeed, it induces sprouting in nerves of patients suffering from Par-
kinson’s disease and amyotrophic lateral sclerosis (Kulshreshtha et al., 
2020; Moller et al., 2011; Ruiz-Roca et al., 2019; Vazquez-Costa et al., 
2016). Clearly, caution must be used when comparing the sprouting 
response at the neuromuscular junction in vivo with neurite outgrowth 
from cultured neurons. Motor nerve terminal sprouting is well estab-
lished to result from blockade of neurotransmitter release (Comella 
et al., 1993; Raghunath et al., 2008; Thesleff et al., 1990) and is part of a 
neurodevelopmental programme that provides new active 
extra-junctional synapses at the NMJ that requires perisynaptic 
Schwann cells (Son and Thompson, 1995). Nonetheless, our data suggest 
that, in addition to the toxic catalytic activity of BoNT/A blocking 
neurotransmitter release, activation of Rac1 and ERK pathways by the 
HCC/A may have important roles in neurogenesis in cultured pyramidal 
neurons. 
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